

# Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

## LA-N-6

RRID:CVCL\_1363

Type: Cell Line

### Proper Citation

RRID:CVCL\_1363

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1363](https://web.expasy.org/cellosaurus/CVCL_1363)

**Proper Citation:** RRID:CVCL\_1363

**Description:** Cell line LA-N-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Neuroblastoma

**Defining Citation:** [PMID:8242562](#), [PMID:11507071](#), [PMID:15150091](#), [PMID:15720811](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:18724359](#), [PMID:20164919](#), [PMID:23202128](#), [PMID:24792489](#), [PMID:25884760](#), [PMID:27397505](#), [PMID:28350380](#), [PMID:28636942](#), [PMID:30894373](#), [PMID:31631027](#), [PMID:35839778](#)

**Comments:** Characteristics: Has long and heterogeneous telomeres and no telomerase activity. Its telomeres shortens continuously at an average rate of 55 base pairs per population doubling (PubMed=28636942)., Characteristics: Neuroblastic type (N-type) (PubMed=15720811)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** LA-N-6

**Synonyms:** LAN-6, LAN6, LA-N-6(OAN)

**Cross References:** CLO:CLO\_0037081, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473429, cancercellines:CVCL\_1363, Cell\_Model\_Passport:SIDM00330, ChEMBL-Cells:ChEMBL3308206, ChEMBL-Targets:ChEMBL2366123, Cosmic:697283, Cosmic:717430, Cosmic:848929,

Cosmic:930067, Cosmic:949170, Cosmic:1019942, Cosmic:1109105, Cosmic:1109366, Cosmic:1161993, Cosmic:1167408, Cosmic:1526630, Cosmic:1890102, Cosmic:2301577, Cosmic:2393637, Cosmic-CLP:949170, DepMap:ACH-001355, DSMZ:ACC-674, DSMZCellDive:ACC-674, EGA:EGAS00001000978, GDSC:949170, GEO:GSM1670032, GEO:GSM2371240, GEO:GSM2394373, IARC\_TP53:23822, IARC\_TP53:27562, LINCS\_LDP:LCL-1988, PharmacoDB:LAN6\_819\_2019, PRIDE:PXD030304, PubChem\_Cell\_line:CVCL\_1363, Wikidata:Q54901879

**ID:** CVCL\_1363

**Record Creation Time:** 20220427T220716+0000

**Record Last Update:** 20260829T234447+0000

---

## Ratings and Alerts

No rating or validation information has been found for LA-N-6.

No alerts have been found for LA-N-6.

---

## Data and Source Information

**Source:** [CelloSaurus](#)

---

## Usage and Citation Metrics

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Price HE, et al. (2026) Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. *Molecular cancer therapeutics*, 25(5), 727.

Subramanian P, et al. (2026) Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(20), e19586.

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. *iScience*, 29(7), 116469.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

Graham MK, et al. (2024) The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. *Cancer research communications*, 4(6), 1533.

Bate-Eya LT, et al. (2024) Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. *Molecular oncology*.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. *Cell reports*, 43(5), 114134.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. *International journal of cancer*, 148(5), 1219.